NCT00044018View on ClinicalTrials.gov

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 1, 2002

Primary Completion Date

December 1, 2004

Study Completion Date

February 15, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

CDC-501

Trial Locations (4)

10011

St Vincent's Cancer Center, New York

33612

H Lee Moffit Cancer Center, Tampa

55902

Mayo Clinic, Rochester

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY